ClinicalTrials.gg
CompletedNCT04219566Updated Oct 21, 2022

Vestibular Nerve Stimulation to Improve Sleep

An interventional study of VeNS and Placebo device in Insomnia, Sleep and Sleep Disorders, Circadian Rhythm, sponsored by Neurovalens Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Neurovalens Ltd. · Not applicable, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Sleep Initiation and Maintenance Disorders with a site in India — 2 open to participants now, 2 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · India.

Started
2020
the only one that year
No phase
8 of 10
2 open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Neurovalens Ltd.

Among the 10 studies in Sleep Initiation and Maintenance Disorders with a site in India, this one is the only one that started in 2020, is one of 8 with no phase, and was the 3rd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 10 studies in Sleep Initiation and Maintenance Disorders with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sleep Initiation and Maintenance Disorders with a site in India, or all of them as a file.
02

Study summary

A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS) compared to a sham control a as a means of improving sleep as measured by ISI scores and EEG recordings

The purpose of this investigation device study is to collect data that will be used to design appropriate pivotal studies that can be used for regulatory submissions, primarily in the United States of America (USA), but it may also be used to support submissions in other regions, including the European Union (EU).

03

Conditions studied

  • Insomnia
  • Sleep
  • Sleep Disorders, Circadian Rhythm
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults
  • Both genders
  • Ages 18-24 years inclusive
  • Score above 14 in the insomnia severity index questionnaire
  • Willingness to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Use sleep medication
  • Ear problems
  • Under any kind of treatment
  • Practicing sleep improving techniques
  • Any other significant health-related problems.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Active VeNS

    The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.

    Device: VeNS

  • Sham comparator
    Sham VeNS

    The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.

    Device: Placebo device

Interventions

  • DeviceVeNS

    Non-invasive electrical vestibular nerve stimulation

  • DevicePlacebo device

    Sham non-invasive electrical vestibular nerve stimulation

06

What researchers measure

Primary outcomes

  1. Change in Insomnia Severity Index (ISI) Scores

    ISI scores will be measured during the study and will be compared to baseline readings taken prior to intervention. Insomnia Severity Index scores range from 0 to 28. Scores greater than 15 indicate clinical insomnia.

    Time frame: Day 0, Day 7, Day 14, Day 21, Day 28

Secondary outcomes

  1. EEG Assessment

    EEG power in alpha band

    Time frame: Day 0, Day 28

  2. Depression Anxiety Stress Scales (DASS) Assessment

    DASS will be measured during the study and will be compared to baseline readings taken prior to intervention. DASS is scored from 0 to 42 with higher scores indicating more symptoms.

    Time frame: Day 0, Day 7, Day 14, Day 21, Day 28

  3. WHO Quality of Life (WHOQOL) Assessment

    QOL will be measured during the study and will be compared to baseline readings taken prior to intervention. WHOQOL is scored from 0 to 100 with higher scores indicating a higher quality of life.

    Time frame: Day 0, Day 7, Day 14, Day 21, Day 28

07

Study locations

1 site
  • RD Gardi Medical College
    Ujjain, Madhya Pradesh 456001, India
08

References and documents

Individual participant data

Plan to share: No — Data will be transferred in an encrypted PDF format. Trial staff will be given direction on how to share the trial data and given access to one specific section of a controlled cloud service which is controlled via role based access. Once they have authenticated with the service and the service verifies that they have the correct role to access the system they will be directed to a single webpage within the application where they will be able to upload the encrypted PDF. This PDF is generated on the fly and is therefore not stored in another location that could become compromised. Generating the PDF on the fly means that the source data is extracted from the database, processed and delivered in the context of a single request. These data will be transferred for each subject when they complete participation in the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jul 2022, 28 months.

Of 78 industry-sponsored interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 28 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2020
First posted
Jan 7, 2020
StartActual
Mar 1, 2020
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Oct 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04219566
Lead sponsor
Neurovalens Ltd.
Collaborators
RD Gardi Medical College, Compliance Solutions Ltd.
Responsible party
Sponsor
First posted
Jan 7, 2020
Start date
Mar 1, 2020
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Oct 21, 2022

Study contacts

Sai Sailesh
principal investigator · RD Gardi Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion